Writing a Clinical Evaluation Report: 5 Quick and Intelligent Tips

January 25, 2020

Writing A Clinical Evaluation Report
Writing a Clinical Evaluation Report: CERtips

“Writing a clinical evaluation report: Sophie Laurenson, healthcare and technology innovator on Kolabtree, shares 5 tips for writing a clinical evaluation report and defining a CER strategy.”

The EU MDR has significantly impacted the way medical devices are regulated in Europe. As part of regulatory compliance, medical device manufacturers need to create and maintain a Clinical Evaluation Report (CER), a document essential for CE Marking. Here are expert tips on what to take into account to define a robust CER strategy.

1. Define a CER protocol and strategy

Identify the Essential Requirements (Safety and Performance Requirements in the MDR) that need to be supported by clinical evidence. Define metrics relative to performance, safety and risk/benefit endpoints.

2. Demonstrate equivalence

Equivalence is determined based on the comparison between a medical device and other pre-existing, similar CE-marked devices. The demonstration of equivalence is evaluated on relevant parameters that are defined by the manufacturer. The rationale for equivalence must be fully explained in the CER. The criteria for equivalence have become complex and stringent, with stronger connections to the Essential Requirements. It is critical to avoid the common mistake of selecting equivalent devices that are not relevant to your product. Documented data must be identified and analyzed for each equivalent device and for the differences between devices.

3. Evaluate literature review data

If equivalency can be demonstrated adequately, clinical data extracted from the literature on previous studies is a valuable tool in compiling a CER. However, it is critical that literature surveys are conducted in a systematic process:

  • Prepare a comprehensive protocol for the literature review,
    • Define inputs and parameters such as databases, search terms and exclusion criteria (languages, study type / design, study setting, endpoints),
    • Define the required safety and performance criteria based on the equivalent products and risk analysis,
    • Systematically gather relevant articles from different data sources,
    • Analyze the data using an objective method such as a framework and using multiple reviewers, and,
    • Document conclusions of the literature evaluation for inclusion in the CER document.

4. Determine the requirement for clinical investigation

The requirement for a clinical investigation is determined by the risk profile of the device. High risk and Class III devices must be subject to a clinical investigation. Novelty is also a determining factor, and devices based on innovative technologies or for a new intended use require clinical investigation. The available clinical evidence must address all the pertinent ERs. This can be ensured by sharing the Clinical Investigational Plan (CIP) with the relevant NB prior to implementation.

5. Monitor post-market activities

Under the MDR, PMS activities must be adequately planned and documented in the CER. The processes for evaluating ongoing clinical data and updating CERs must also be documented. To ensure that the CER remains relevant throughout the product life cycle, it must be updated regularly through a documented process. This includes evaluating the data and weighing the relevance of all equivalent devices. If you need help with writing a CER, it’s worth hiring a freelance Clinical Evaluation Report writer who can help you prepare and maintain a robust CER that meets all regulatory requirements.

Author bio:
Sophie Laurenson BSc. (Hons), Ph.D. (Cantab) has over 17 years of professional experience in healthcare, in both industry and academia. She consults on Kolabtree for medtech startups and SMBs. She previously worked in R&D functions at Abbott Laboratories in the United Kingdom, Germany, and Switzerland. She has experience in academic spin-outs and is the Founder and Managing Director of a health technology start-up specializing in emerging markets. Her areas of expertise include medical technology, digital health, and healthcare delivery technology. She is an expert on the subject of writing a clinical evaluation report. Another article of interest for device companies can be found here.

 

SourceKolabtree

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”